For those of you, who like us, miss the addictive hit TV series, 24, in which Jack Bauer (Kiefer Sutherland) and his fellow agents race around the clock to save the world from disaster, some excellent news: starting January 2, EpicentRx debuted its own fast-paced, adrenaline-fueled thriller called “2024 LIVE MANY MORE YEARS” where CEO Tony Reid and the rest of the EpicentRx team set out to bring down cancer and other dread diseases / conditions like SCLC, severe oral mucositis, Parkinson’s, ALS/MND, and endometriosis over the span of the whole year, rather than just 24 hours.
The action-packed, unmissable 1st Season revolves around RRx-001 and AdAPT-001 in several clinical and preclinical studies: the first is a Phase 3 clinical trial of RRx-001 against small cell lung cancer (SCLC) called REPLATINUM, the second is a Phase 2b clinical trial of RRx-001 against severe oral mucositis, the third is a Phase 2 clinical trial of AdAPT-001 with a checkpoint inhibitor against sarcomas, the fourth is a grant-funded Phase 1 trial of RRx-001 against endometriosis, and the fifth is several grant-funded preclinical studies of RRx-001 in neurodegenerative diseases like Parkinson’s and ALS/MND.
So, buckle up and hang on tight as the EpicentRx team and their lead therapeutic molecules put it all the line in a white-knuckle, roller-coaster race to the finish against two age-old enemies, disease, and time.
Cue the 2024 countdown clock and the intense heart-monitor-like BEEP THUNK BEEP THUNK BEEP THUNK sound that goes with it.